NASDAQ: LPTX
Leap Therapeutics Inc Stock

$0.32+0.04 (+14.29%)
Updated Jul 8, 2025
LPTX Price
$0.32
Fair Value Price
N/A
Market Cap
$13.18M
52 Week Low
$0.22
52 Week High
$4.79
P/E
-0.19x
P/B
0.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$69.17M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.67
Operating Cash Flow
-$59M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

LPTX Overview

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LPTX's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
LPTX
Ranked
Unranked of 475

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important LPTX news, forecast changes, insider trades & much more!

LPTX News

Overview

Due Diligence Score

–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LPTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LPTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LPTX is good value based on its book value relative to its share price (0.63x), compared to the US Biotechnology industry average (4.53x)
P/B vs Industry Valuation
LPTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LPTX due diligence checks available for Premium users.

Valuation

LPTX fair value

Fair Value of LPTX stock based on Discounted Cash Flow (DCF)

Price
$0.32
Fair Value
$1.25
Undervalued by
74.42%
LPTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LPTX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.19x
Industry
-136.92x
Market
30.75x

LPTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.63x
Industry
4.53x
LPTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LPTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$15.4M
Profit Margin
0%
LPTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$34.9M
Liabilities
$14.0M
Debt to equity
0.67
LPTX's short-term assets ($33.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LPTX's short-term assets ($33.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LPTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LPTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.5M
Investing
$0.0
Financing
-$61.0k
LPTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LPTX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LPTX–$13.18M+11.97%-0.19x0.63x
PTHS–$13.11M-23.39%-1.60x-3.13x
PMN–$13.08M-2.20%-8.00x1.38x
BRTX–$12.91M+13.16%-1.17x2.10x
NEUP–$13.54M+0.56%N/A0.81x

Leap Therapeutics Stock FAQ

What is Leap Therapeutics's quote symbol?

(NASDAQ: LPTX) Leap Therapeutics trades on the NASDAQ under the ticker symbol LPTX. Leap Therapeutics stock quotes can also be displayed as NASDAQ: LPTX.

If you're new to stock investing, here's how to buy Leap Therapeutics stock.

What is the 52 week high and low for Leap Therapeutics (NASDAQ: LPTX)?

(NASDAQ: LPTX) Leap Therapeutics's 52-week high was $4.79, and its 52-week low was $0.22. It is currently -93.36% from its 52-week high and 43.24% from its 52-week low.

How much is Leap Therapeutics stock worth today?

(NASDAQ: LPTX) Leap Therapeutics currently has 41,439,529 outstanding shares. With Leap Therapeutics stock trading at $0.32 per share, the total value of Leap Therapeutics stock (market capitalization) is $13.18M.

Leap Therapeutics stock was originally listed at a price of $78.60 in Jan 25, 2017. If you had invested in Leap Therapeutics stock at $78.60, your return over the last 8 years would have been -99.6%, for an annualized return of -49.78% (not including any dividends or dividend reinvestments).

How much is Leap Therapeutics's stock price per share?

(NASDAQ: LPTX) Leap Therapeutics stock price per share is $0.32 today (as of Jul 8, 2025).

What is Leap Therapeutics's Market Cap?

(NASDAQ: LPTX) Leap Therapeutics's market cap is $13.18M, as of Jul 9, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Leap Therapeutics's market cap is calculated by multiplying LPTX's current stock price of $0.32 by LPTX's total outstanding shares of 41,439,529.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.